Spots Global Cancer Trial Database for advanced melanoma
Every month we try and update this database with for advanced melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | NCT05549297 | Advanced Melano... | Tebentafusp Tebentafusp wit... Investigators C... | 18 Years - | Immunocore Ltd | |
| Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan | NCT02402699 | Advanced Melano... Hepatitis B Hepatitis C | 18 Years - | Bristol-Myers Squibb | ||
| APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | NCT03502330 | Advanced Melano... Non-small Cell ... Renal Cell Carc... | APX005M Cabiralizumab Nivolumab | 18 Years - | Yale University | |
| Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | NCT02452281 | Melanoma | ipilimumab HSPPC-96 | 18 Years - | The University of Texas Health Science Center, Houston | |
| A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma | NCT04640545 | Advanced Melano... | LBL-007 Toripalimab Axitinib Tablet... | 18 Years - | Nanjing Leads Biolabs Co.,Ltd | |
| Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma | NCT04796194 | Advanced Melano... | LTX-315 in comb... | 18 Years - | Lytix Biopharma AS | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| Exercise and Diet Interventions During Immunotherapy in Melanoma Patients | NCT06298734 | Melanoma (Skin) Skin Cancer Advanced Melano... | Exercise Progra... Diet Program | 18 Years - | Dana-Farber Cancer Institute | |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | NCT05039801 | Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri... | Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma | NCT03013101 | Advanced Melano... Metastatic Mela... | humanized anti-... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database | NCT05426239 | Advanced Melano... | 18 Years - | Bristol-Myers Squibb | ||
| A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma | NCT05907122 | Melanoma | ABP 206 FDA-licensed Ni... EU-authorized N... | 18 Years - 99 Years | Amgen | |
| A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | NCT02302339 | Melanoma | glembatumumab v... glembatumumab v... glembatumumab v... glembatumumab v... | 18 Years - | Celldex Therapeutics | |
| A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | NCT03311308 | Advanced Melano... | Pembrolizumab I... Metformin | 18 Years - | University of Pittsburgh | |
| A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | NCT03445533 | Metastatic Mela... | Ipilimumab Tilsotolimod wi... | 18 Years - | Idera Pharmaceuticals, Inc. | |
| An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma | NCT01078961 | Melanoma | bortezomib sorafenib | 18 Years - | Massachusetts General Hospital | |
| Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | NCT01603212 | Melanoma | Vemurafenib IL-2 Interferon Alph... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | NCT04514484 | Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi... | Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | NCT06112808 | Advanced Melano... | BCD-263 Opdivo | 18 Years - | Biocad | |
| Naltrexone and Propranolol Combined With Immunotherapy | NCT05968690 | Advanced Melano... | Propranolol Naltrexone | 18 Years - | Rutgers, The State University of New Jersey | |
| VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3) | NCT06264180 | Advanced Melano... | Vusolimogene Od... Nivolumab Nivolumab + Rel... Pembrolizumab Single-agent ch... | 12 Years - | Replimune Inc. | |
| Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma | NCT04951583 | Non Small Cell ... Advanced Melano... | FMT + ICI | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma | NCT03013101 | Advanced Melano... Metastatic Mela... | humanized anti-... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | NCT02452281 | Melanoma | ipilimumab HSPPC-96 | 18 Years - | The University of Texas Health Science Center, Houston | |
| Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma | NCT01614301 | Advanced Melano... | dacarbazine (DT... | 18 Years - | University of Regensburg | |
| Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | NCT03407170 | Advanced Melano... | pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Clinical Study of T3011 in Subjects With Advanced Melanoma | NCT06214156 | Advanced Melano... | T3011 | 18 Years - | Shanghai Pharmaceuticals Holding Co., Ltd | |
| Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) | NCT03776136 | Advanced Melano... | lenvatinib pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma | NCT01614301 | Advanced Melano... | dacarbazine (DT... | 18 Years - | University of Regensburg | |
| A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma | NCT01227889 | Cancer | GSK2118436 Dacarbazine (DT... | 18 Years - | GlaxoSmithKline | |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | NCT02965716 | Advanced Melano... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me... | Pembrolizumab Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | NCT02981303 | Advanced Melano... Triple-Negative... | Imprime PGG Pembrolizumab | 18 Years - | HiberCell, Inc. | |
| FLX475 in Combination With Ipilimumab in Advanced Melanoma | NCT04894994 | Advanced Melano... | FLX475 Ipilimumab | 18 Years - | RAPT Therapeutics, Inc. | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| Phase II Study of Tesetaxel in Metastatic Melanoma | NCT01064713 | Advanced Melano... Cancer | Tesetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study | NCT03707574 | Advanced Malign... Advanced Melano... Advanced Renal ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Color... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage IIIA Colo... Stage IIIA Lung... Stage IIIA Ovar... Stage IIIA Pros... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Colo... Stage IIIB Lung... Stage IIIB Ovar... Stage IIIB Pros... Stage IIIC Colo... Stage IIIC Lung... Stage IIIC Ovar... Stage IIIC Pros... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IVA Color... Stage IVA Lung ... Stage IVA Ovari... Stage IVA Prost... Stage IVB Color... Stage IVB Lung ... Stage IVB Ovari... Stage IVB Prost... Stage IVC Color... | Biospecimen Col... | 18 Years - | National Cancer Institute (NCI) | |
| A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma | NCT01227889 | Cancer | GSK2118436 Dacarbazine (DT... | 18 Years - | GlaxoSmithKline | |
| Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma | NCT02656706 | Melanoma | Ipilumumab Nivolumab | 18 Years - | Brown University | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | NCT02836548 | Melanoma Skin Neoplasms | Vorinostat | - | The Netherlands Cancer Institute | |
| Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | NCT02452281 | Melanoma | ipilimumab HSPPC-96 | 18 Years - | The University of Texas Health Science Center, Houston | |
| Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma | NCT01764009 | Melanoma | naked DNA codin... | 18 Years - | Valerio Therapeutics | |
| Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | NCT04493203 | Advanced Melano... Unresectable Me... | Nivolumab Axitinib | 18 Years - | University of Pittsburgh | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor | NCT01619774 | Melanoma | GSK2118436 GSK1120212 | 16 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) | NCT03776136 | Advanced Melano... | lenvatinib pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation | NCT05114603 | Advanced Melano... | HLX208 | 18 Years - | Shanghai Henlius Biotech | |
| CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | NCT04695977 | Melanoma Advanced Melano... Metastatic Mela... Unresectable Me... | CMP-001 Nivolumab | 18 Years - | Regeneron Pharmaceuticals | |
| Trial of Dacarbazine With or Without Genasense in Advanced Melanoma | NCT00518895 | Melanoma | dacarbazine plu... dacarbazine plu... | 18 Years - | Genta Incorporated | |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | NCT05039801 | Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri... | Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | NCT01864538 | Metastatic Mela... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma | NCT00813449 | Advanced Melano... Untreated Patie... | dacarbazine plu... dacarbazine plu... | 18 Years - 75 Years | Simcere Pharmaceutical Co., Ltd | |
| ACT-TIL and ANV419 for Advanced Melanoma. | NCT05869539 | Advanced Melano... | Combination of ... | 18 Years - | University Hospital, Basel, Switzerland | |
| Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. | NCT00688090 | Advanced Melano... Stage III and I... | Biological: MKC... Biological: MKC... | 18 Years - | Mannkind Corporation | |
| A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation | NCT05114603 | Advanced Melano... | HLX208 | 18 Years - | Shanghai Henlius Biotech | |
| Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | NCT03724968 | Metastatic Mela... Advanced Melano... Metastatic Mela... | Nivolumab Relatlimab Ipilimumab | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | NCT06112808 | Advanced Melano... | BCD-263 Opdivo | 18 Years - | Biocad | |
| Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma | NCT04165967 | Advanced Melano... | Combination of ... | 18 Years - 75 Years | University Hospital, Basel, Switzerland | |
| A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | NCT01864538 | Metastatic Mela... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors | NCT01618136 | Malignant Solid... Ovarian Cancer Triple Negative... Advanced Melano... B-cell Malignan... | E7449 alone E7449 plus TMZ E7449 plus carb... | 18 Years - | Eisai Inc. | |
| ACT-TIL and ANV419 for Advanced Melanoma. | NCT05869539 | Advanced Melano... | Combination of ... | 18 Years - | University Hospital, Basel, Switzerland | |
| Abraxane and Temodar Plus Genasense in Advanced Melanoma | NCT00409383 | Melanoma | Genasense® (obl... Abraxane® (pacl... Temodar® (temoz... | 18 Years - | Genta Incorporated | |
| Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan | NCT02402699 | Advanced Melano... Hepatitis B Hepatitis C | 18 Years - | Bristol-Myers Squibb | ||
| Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma | NCT03990493 | Advanced Melano... | Dengue Virus-1 ... Autologous Mono... | 18 Years - | PrimeVax Immuno-Oncology Inc. | |
| XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy | NCT05695898 | Metastatic Mela... Advanced Melano... | XmAb22841 XmAb23104 | 18 Years - | University of California, San Francisco | |
| A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine | NCT00542893 | Advanced Melano... | Genasense® (G31... Genasense follo... DTIC alone; the... | 18 Years - | Genta Incorporated | |
| A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | NCT02302339 | Melanoma | glembatumumab v... glembatumumab v... glembatumumab v... glembatumumab v... | 18 Years - | Celldex Therapeutics | |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | NCT04902040 | Advanced Bladde... Advanced Lung N... Advanced Malign... Advanced Melano... Advanced Merkel... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IVA Bladd... Stage IVA Lung ... Stage IVB Bladd... Stage IVB Lung ... | Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases | NCT03448666 | Malignant Melan... | Pembrolizumab | 18 Years - | European Institute of Oncology | |
| Nab-PCE vs PC for MM After Failure of Anti-PD-1 | NCT03917069 | Advanced Melano... | Chemotherapeuti... chemotherapy | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
| Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | NCT03200847 | Stage IV Melano... Stage III Melan... Advanced Melano... | Pembrolizumab w... | 18 Years - 100 Years | University of Colorado, Denver | |
| Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | NCT02452281 | Melanoma | ipilimumab HSPPC-96 | 18 Years - | The University of Texas Health Science Center, Houston | |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | NCT04902040 | Advanced Bladde... Advanced Lung N... Advanced Malign... Advanced Melano... Advanced Merkel... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IVA Bladd... Stage IVA Lung ... Stage IVB Bladd... Stage IVB Lung ... | Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII | NCT03818893 | Advanced Melano... | Combination of ... | 20 Years - 85 Years | Osaka University | |
| Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma | NCT02656706 | Melanoma | Ipilumumab Nivolumab | 18 Years - | Brown University | |
| Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma | NCT01616199 | Advanced BRAF-m... | PX-866 vemurafenib | 18 Years - | Seagen Inc. | |
| A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma | NCT00746746 | Melanoma | HyperAcute vacc... Pegylated Inter... | 19 Years - | Ochsner Health System | |
| A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | NCT04495257 | Advanced Melano... Renal Cell Carc... | Nivolumab Ipilimumab APX005M | 18 Years - | Yale University | |
| Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma | NCT00920907 | Advanced Melano... | Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma | NCT05466474 | Advanced Melano... | Tislelizumab In... | 18 Years - 72 Years | Henan Cancer Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
